Klaria Pharma Holding AB (SE0007280326)

Overview

Klaria Pharma Holding AB (publ.) is a pharmaceutical company established in 2014, with its headquarters located in Uppsala, Sweden. It is dedicated to the development and commercialization of innovative treatments for various medical conditions. The company concentrates on leveraging its expertise in the pharmaceutical field to deliver effective solutions for migraines, acute allergic reactions, organ transplant rejection prevention, and the therapeutic applications of cannabis and cannabinoids.

Products and Services

• Sumatriptan

  This is a medication developed for the treatment of migraine headaches. Sumatriptan works by narrowing blood vessels around the brain and reduces substances in the body that can trigger headache pain, nausea, sensitivity to light and sound, and other migraine symptoms. Klaria Pharma Holding endeavors to offer a novel formulation of this medication to enhance its efficacy and patient convenience.

• Epinephrine/Adrenaline

  Currently in Phase I clinical trial, this product is being developed for the emergency treatment of acute allergic reactions (anaphylaxis). Epinephrine is crucial for managing severe allergic reactions caused by foods, insect stings, medications, or other triggers. Through its development, the company aims to provide a reliable and accessible emergency solution for patients at risk of anaphylaxis.

• Sirolimus

  This pre-clinical product is under research for its potential in the prevention of organ transplant rejection. Sirolimus, also known as rapamycin, is known for its immunosuppressive properties, which can help in prolonging the life of transplanted organs. Klaria Pharma is exploring innovative applications of Sirolimus to improve outcomes for transplant recipients.

• Cannabis/Cannabinoids

  The company also focuses on the commercialization of cannabis and cannabinoids for therapeutic uses. Recognizing the potential broad therapeutic applications of cannabinoids, Klaria Pharma is engaging in research and development efforts to harness these compounds for the treatment of various conditions, aiming to expand its portfolio into this emerging area of medicine.